Related Experiment Video
Updated: Jun 24, 2026
Cell Labeling and Targeting with Superparamagnetic Iron Oxide Nanoparticles
Published on: October 19, 2015
PAD4 Inhibitor-Loaded Magnetic Fe3O4 Nanoparticles for Magnetic Targeted Chemotherapy and Magnetic Resonance Imaging
Yu Lu1,2, Xin Wang1,2, Yijiang Jia1,2
1Department of Medicinal Chemistry, College of Pharmaceutical Sciences of Capital Medical University, Beijing, 100069, People's Republic of China.
Introduction:
Lung cancer is a major health concern worldwide owing to its high incidence and mortality rates. Therefore, identification of new therapeutic targets and strategies for lung cancer is critical for improving patient outcomes. Peptidyl arginine deiminase 4 (PAD4) promotes tumor growth and metastasis by catalyzing the citrullination of histones, making it a potential therapeutic target. Although PAD4 inhibitors have shown potential in the treatment of a variety of tumors, existing PAD4 inhibitors lack sufficient specificity and cause substantial systemic adverse reactions. To overcome these challenges, we developed novel YW403@Fe3O4-oxidized carboxymethyl chitosan (OCMC) magnetic nanoparticles (MNPs) that enabled magnetically targeted drug delivery by binding the PAD4 inhibitor YW403 to a ferric oxide magnetic carrier.
Methods:
In vitro experiments were conducted using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, Transwell assays, and flow cytometry to evaluate the activity of the MNPs. In vivo experiments involved magnetic resonance imaging (MRI) assessments and inductively coupled plasma mass spectrometry (ICP-MS) analyses to confirm the tumor targeting and iron metabolism of MNPs. Additionally, immunofluorescence staining was employed to further validate the expression of citrullinated histone H3 (H3cit).
Results:
The implementation of this approach enhanced the targeting efficiency of PAD4 inhibitors, consequently reducing the required dosage of chemotherapy and potentially facilitating MRI monitoring. In vitro experiments demonstrated that MNPs exhibited superior activity compared to free drugs when subjected to an applied magnetic field, due to increased uptake of MNPs by tumor cells. In vivo experiments revealed that the application of magnetic fields significantly improved the tumor targeting of MNPs without impacting iron metabolism. By suppressing the expression of citrullinated histone (H3cit), MNPs effectively inhibited tumor growth and metastasis.
Discussion:
These findings provide new research ideas for the development of novel anti-tumor nanomaterials and are expected to yield breakthroughs in the treatment of lung cancer.
Insights
Novel magnetic nanoparticles loaded with a peptidyl arginine deiminase 4 (PAD4) inhibitor show enhanced lung cancer targeting and reduced side effects. This magnetic drug delivery system improves therapeutic efficacy and allows for MRI monitoring, offering a promising new strategy for lung cancer treatment.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Lung cancer presents a significant global health challenge with high incidence and mortality.
- Peptidyl arginine deiminase 4 (PAD4) is implicated in tumor growth and metastasis, making it a potential therapeutic target.
- Existing PAD4 inhibitors have limitations in specificity and cause systemic adverse effects.
Purpose of the Study:
- To develop novel magnetic nanoparticles (MNPs) for targeted delivery of a PAD4 inhibitor (YW403).
- To evaluate the efficacy and safety of YW403@Fe3O4-oxidized carboxymethyl chitosan (OCMC) MNPs in lung cancer treatment.
- To explore the potential for MRI monitoring of MNP delivery.
Main Methods:
- In vitro studies utilized MTT assays, Transwell assays, and flow cytometry to assess MNP activity.
- In vivo studies involved MRI and ICP-MS to confirm tumor targeting and iron metabolism.
- Immunofluorescence staining was used to validate the suppression of citrullinated histone H3 (H3cit).
Main Results:
- MNPs demonstrated superior in vitro activity compared to free drugs under magnetic field application due to enhanced tumor cell uptake.
- In vivo magnetic field application significantly improved MNP tumor targeting without altering iron metabolism.
- MNPs effectively inhibited lung cancer growth and metastasis by suppressing H3cit expression.
Conclusions:
- The developed YW403@Fe3O4-OCMC MNPs offer enhanced targeting efficiency for PAD4 inhibitors, reducing chemotherapy dosage and enabling MRI monitoring.
- This magnetically targeted drug delivery system represents a novel approach for lung cancer therapy.
- The findings provide a foundation for developing advanced anti-tumor nanomaterials and improving lung cancer treatment outcomes.
Related Concept Videos
01:24Magnetic Resonance Imaging
01:27Imaging Studies IV: Magnetic Resonance Imaging